OOIR: Observatory of International Research

Papers

(The H4-Index of Neurobiology of Disease is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood–brain barrier	308
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine	229
Microglia and astrocyte dysfunction in parkinson's disease	171
The microbiota-immune axis as a central mediator of gut-brain communication	106
Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation	105
Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis	99
Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease	97
How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synucle	91
Long-lasting blood-brain barrier dysfunction and neuroinflammation after traumatic brain injury	88
Mitochondrial fission in Huntington's disease mouse striatum disrupts ER-mitochondria contacts leading to disturbances in Ca2+ efflux and Reactive Oxygen Species (ROS) homeostasis	84
APOE in the normal brain	80
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease	77
Microglia reprogram metabolic profiles for phenotype and function changes in central nervous system	76
Fragile X syndrome and associated disorders: Clinical aspects and pathology	74
Microglia depletion rapidly and reversibly alters amyloid pathology by modification of plaque compaction and morphologies	73
Genetic architecture of Alzheimer's disease	72
Plasmalogens, platelet-activating factor and beyond – Ether lipids in signaling and neurodegeneration	72
Neuropathological evidence of body-first vs. brain-first Lewy body disease	69
The wrinkling of time: Aging, inflammation, oxidative stress, and the circadian clock in neurodegeneration	69
Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports	68
CRISPR/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice	65
Beyond the CNS: The many peripheral roles of APOE	65
Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease	65
APOE-amyloid interaction: Therapeutic targets	62
INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia	62

Oligomeric α-Syn and SNARE complex proteins in peripheral extracellular vesicles of neural origin are biomarkers for Parkinson's disease	61
APOE alters glucose flux through central carbon pathways in astrocytes	61
Shifting paradigms: The central role of microglia in Alzheimer's disease	58
It's complicated: The relationship between sleep and Alzheimer's disease in humans	58
Obstructive Sleep Apnea and Its Treatment in Aging: Effects on Alzheimer’s disease Biomarkers, Cognition, Brain Structure and Neurophysiology	56
Glia: victims or villains of the aging brain?	55
The contribution of glial cells to Huntington's disease pathogenesis	54
Loss of Parkin contributes to mitochondrial turnover and dopaminergic neuronal loss in aged mice	53
Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons	52
Systematic review and meta-analysis of human transcriptomics reveals neuroinflammation, deficient energy metabolism, and proteostasis failure across neurodegeneration	52
Alzheimer's-associated PU.1 expression levels regulate microglial inflammatory response	52
TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia	52
An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease	51
Clinical and imaging evidence of brain-first and body-first Parkinson's disease	51
Immunotherapy for Parkinson’s disease	51
Cilia, ciliopathies and hedgehog-related forebrain developmental disorders	50
Glia in neurodegeneration: Drivers of disease or along for the ride?	50
Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation	49
The genetic architecture of ALS	48
Deficient astrocyte metabolism impairs glutamine synthesis and neurotransmitter homeostasis in a mouse model of Alzheimer's disease	48
Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study	48
Defining molecular identity and fates of CNS-border associated macrophages after ischemic stroke in rodents and humans	48
Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease	47
Single-cell RNA-seq analysis of the brainstem of mutant SOD1 mice reveals perturbed cell types and pathways of amyotrophic lateral sclerosis	47